First Trust Advisors’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-39,783
| Closed | -$5.1M | – | 2593 |
|
|
2025
Q2 | $5.1M | Buy |
39,783
+36,603
| +1,151% | +$3.8M | ﹤0.01% | 1349 |
|
|
2025
Q1 | $281K | Sell |
3,180
-50,525
| -94% | -$4.93M | ﹤0.01% | 2383 |
|
|
2024
Q4 | $4.68M | Sell |
53,705
-1,123
| -2% | -$103K | ﹤0.01% | 1393 |
|
|
2024
Q3 | $5.07M | Sell |
54,828
-5,310
| -9% | -$527K | ﹤0.01% | 1335 |
|
|
2024
Q2 | $6.48M | Buy |
60,138
+12,867
| +27% | +$1.29M | 0.01% | 1164 |
|
|
2024
Q1 | $4.48M | Buy |
+47,271
| New | +$4.05M | ﹤0.01% | 1349 |
|
|
2023
Q1 | – | Sell |
-31,597
| Closed | -$1.38M | – | 2366 |
|
|
2022
Q4 | $1.38M | Buy |
31,597
+24,333
| +335% | +$1.17M | ﹤0.01% | 1852 |
|
|
2022
Q3 | $479K | Sell |
7,264
-3,684
| -34% | -$237K | ﹤0.01% | 2224 |
|
|
2022
Q2 | $553K | Buy |
10,948
+842
| +8% | +$49.3K | ﹤0.01% | 2169 |
|
|
2022
Q1 | $646K | Sell |
10,106
-44,007
| -81% | -$3.16M | ﹤0.01% | 2189 |
|
|
2021
Q4 | $5.8M | Buy |
54,113
+41,306
| +323% | +$4.32M | 0.01% | 1298 |
|
|
2021
Q3 | $1.32M | Sell |
12,807
-11,383
| -47% | -$1.06M | ﹤0.01% | 1937 |
|
|
2021
Q2 | $2.13M | Sell |
24,190
-28,544
| -54% | -$2.62M | ﹤0.01% | 1784 |
|
|
2021
Q1 | $5.13M | Buy |
52,734
+2,286
| +5% | +$228K | 0.01% | 1227 |
|
|
2020
Q4 | $5.66M | Buy |
50,448
+22,646
| +81% | +$2.39M | 0.01% | 1048 |
|
|
2020
Q3 | $2.58M | Buy |
27,802
+12,439
| +81% | +$958K | ﹤0.01% | 1246 |
|
|
2020
Q2 | $1.2M | Buy |
+15,363
| New | +$1.04M | ﹤0.01% | 1649 |
|
|
2019
Q4 | – | Sell |
-62,690
| Closed | -$4.61M | – | 2387 |
|
|
2019
Q3 | $4.61M | Buy |
62,690
+20,042
| +47% | +$1.73M | 0.01% | 1097 |
|
|
2019
Q2 | $4.02M | Buy |
42,648
+28,349
| +198% | +$2.34M | 0.01% | 1187 |
|
|
2019
Q1 | $1.15M | Sell |
14,299
-11,482
| -45% | -$848K | ﹤0.01% | 1810 |
|
|
2018
Q4 | $1.39M | Buy |
+25,781
| New | +$1.57M | ﹤0.01% | 1686 |
|
|
2018
Q3 | – | Sell |
-24,702
| Closed | -$1.57M | – | 2438 |
|
|
2018
Q2 | $1.57M | Sell |
24,702
-36,483
| -60% | -$2.9M | ﹤0.01% | 1737 |
|
|
2018
Q1 | $5.61M | Buy |
61,185
+33,276
| +119% | +$2.87M | 0.01% | 980 |
|
|
2017
Q4 | $2.1M | Sell |
27,909
-20,046
| -42% | -$1.41M | 0.01% | 1496 |
|
|
2017
Q3 | $3.34M | Sell |
47,955
-9,726
| -17% | -$520K | 0.01% | 1181 |
|
|
2017
Q2 | $2.92M | Buy |
+57,681
| New | +$2.45M | 0.01% | 1247 |
|
Other funds holding BPMC
IA
HNB
First Trust Advisors's BPMC Position: Q3 2025 in Review
First Trust Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 39,783 shares — an estimated $5.1M sold.
First Trust Advisors first reported a position in BPMC in Q2 2017 and held it in 26 quarters. The position peaked at $6.48M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- First Trust Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- First Trust Advisors sold 39,783 Blueprint Medicines shares in Q3 2025, an estimated $5.1M.
- First Trust Advisors first reported a position in Blueprint Medicines in Q2 2017 and held it in 26 quarters.
- First Trust Advisors's Blueprint Medicines position peaked at $6.48M in Q2 2024.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on First Trust Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.